Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity

被引：0
|
作者：
Huck, C. [1 ]
Wegert, V. [1 ]
Schmid, C. [1 ]
Dunn, B. [2 ]
Smith, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
[2] Novartis Inst Funct Genom Inc, San Diego, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P401
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [41] The Levels of Memory B-Cells with a Plasmablast-Like Phenotype Are Associated with Response to Anti-CD20 Treatment in Rheumatoid Arthritis
    Arumugakani, Gururaj
    Rawstron, Andrew
    Tooze, Reuben
    Emery, Paul
    McGonagle, Dennis
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S681 - S681
  • [42] Anti-CD20 therapy ameliorates beta cell function and rebalances Th17/Treg cells in NOD mice
    Chen, Min
    Zhang, Qianhui
    Wei, Yanhong
    Wan, Qianqian
    Xu, Min
    Chen, Xiaoqi
    ENDOCRINE, 2022, 76 (01) : 44 - 52
  • [43] Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy
    Takahira, Masayuki
    Okumura, Hirokazu
    Minato, Hiroshi
    Urushisaki, Norimasa
    Sakurai, Mayumi
    Sugiyama, Kazuhisa
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2007, 51 (02) : 149 - 151
  • [44] The applications of anti-CD20 antibodies to treat various B cells disorders
    Payandeh, Zahra
    Bahrami, Armina Alagheband
    Hoseinpoor, Reyhaneh
    Mortazavi, Yousef
    Rajabibazl, Masoumeh
    Rahimpour, Azam
    Taromchi, Amir Hossein
    Khalil, Saeed
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 : 2415 - 2426
  • [45] Following anti-CD20 treatment, repletion kinetic and immune-competence of reappearing B-cells depends on peripheral stimulation
    Feldmann, L.
    Zamvil, S.
    Brueck, W.
    Weber, M. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 140 - 141
  • [46] Primary Conjunctival Follicular Lymphoma Treated with the Anti-CD20 Antibody Rituximab and Low-Dose Involved-Field Radiotherapy
    Masayuki Takahira
    Hirokazu Okumura
    Hiroshi Minato
    Norimasa Urushisaki
    Mayumi Sakurai
    Kazuhisa Sugiyama
    Japanese Journal of Ophthalmology, 2007, 51 : 149 - 151
  • [47] HDAC6 INHIBITION AUGMENTS THE EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES BY UP-REGULATING CD20 LEVEL IN MALIGNANT B-CELLS
    Bobrowicz, M.
    Dwojak, M.
    Bojarczuk, K.
    Siernicka, M.
    Winiarska, M.
    Golab, J.
    HAEMATOLOGICA, 2014, 99 : 437 - 437
  • [48] CD11c+ B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy
    El Mahdaoui, Sahla
    Hansen, Marie Mathilde
    von Essen, Marina Rode
    Hvalkof, Victoria Hyslop
    Hansen, Rikke Holm
    Mahler, Mie Reith
    Jennum, Poul
    Sellebjerg, Finn
    Christensen, Jeppe Romme
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (04): : 926 - 937
  • [49] Inflammatory microenvironment rescues B-Cells of tertiary lymphoid organs from anti-CD20 therapy during chronic antibody-mediated rejection.
    Thaunat, Olivier
    Patey, Natacha
    Gautreau, Chantal
    Nicoletti, Antonino
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 448 - 448
  • [50] OCARATUZUMAB, A FAB-ENGINEERED ANTI-CD20 ANTIBODY, DEMONSTRATES GREATER AFFINITY TO CD20 AND ABILITY TO BIND TO RITUXIMAB-COATED B-CELLS
    O'Reilly, A.
    Davis, T.
    Wayne, J.
    Marulappa, S.
    Jain, V.
    HAEMATOLOGICA, 2012, 97 : 440 - 440
12345